But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
ApexOnco Front Page
Recent articles
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Inclacumab fails, and osivelotor is on hold.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Shortly after ponsegromab, visugromab is to start phase 2/3.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
Keynote-D18 might have failed on a technicality, but now cash is running out.
